Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian E Serfling

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2023
Theranostics in HematooncologyAndreas K Buck, Sebastian E Serfling, Sabrina Kraus, et al.
Clinical Nuclear Medicine|April 19, 2022
Rechallenge With Additional Doses of 177 Lu-DOTATOC After Failure of Maintenance Therapy With Cold Somatostatin AnalogsAlexander Weich, Rudolf A Werner, Sebastian E Serfling, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 15, 2022
Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinomaRudolf A Werner, Cyrus Sayehli, Heribert Hänscheid, et al.
Cancers|June 10, 2022
Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission TomographyAleksander Kosmala, Sebastian E Serfling, Niklas Dreher, et al.
Clinical Nuclear Medicine|February 13, 2024
Exploring Theranostic Avenues in Adrenocortical Carcinoma Using Chemokine Receptor and Prostate-Specific Membrane Antigen-Directed PET/CTStefanie Hahner, Takahiro Higuchi, Sebastian E Serfling, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 19, 2024
Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinomaWiebke Schloetelburg, Philipp E Hartrampf, Aleksander Kosmala, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 2, 2025
SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factorsNatalie Hasenauer, Miriam Müller, Heribert Hänscheid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
[<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-04 Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine NeoplasmsKerstin Michalski, Aleksander Kosmala, Philipp E Hartrampf, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 1, 2022
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA I&T during long-term follow-upPhilipp E Hartrampf, Anna Katharina Seitz, Franz-Xaver Weinzierl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 16, 2026
CXCR4-targeted PET/CT in early systemic sclerosis-associated interstitial lung disease: a prospective proof-of-concept study of in vivo inflammatory activityMichael Gernert, Marc Schmalzing, Hannah Labinsky, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2023
Theranostics in HematooncologyAndreas K Buck, Sebastian E Serfling, Sabrina Kraus, et al.
Clinical Nuclear Medicine|April 19, 2022
Rechallenge With Additional Doses of 177 Lu-DOTATOC After Failure of Maintenance Therapy With Cold Somatostatin AnalogsAlexander Weich, Rudolf A Werner, Sebastian E Serfling, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 15, 2022
Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinomaRudolf A Werner, Cyrus Sayehli, Heribert Hänscheid, et al.
Cancers|June 10, 2022
Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission TomographyAleksander Kosmala, Sebastian E Serfling, Niklas Dreher, et al.
Clinical Nuclear Medicine|February 13, 2024
Exploring Theranostic Avenues in Adrenocortical Carcinoma Using Chemokine Receptor and Prostate-Specific Membrane Antigen-Directed PET/CTStefanie Hahner, Takahiro Higuchi, Sebastian E Serfling, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 19, 2024
Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinomaWiebke Schloetelburg, Philipp E Hartrampf, Aleksander Kosmala, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 2, 2025
SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factorsNatalie Hasenauer, Miriam Müller, Heribert Hänscheid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
[<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-04 Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine NeoplasmsKerstin Michalski, Aleksander Kosmala, Philipp E Hartrampf, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 1, 2022
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA I&T during long-term follow-upPhilipp E Hartrampf, Anna Katharina Seitz, Franz-Xaver Weinzierl, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 16, 2026
CXCR4-targeted PET/CT in early systemic sclerosis-associated interstitial lung disease: a prospective proof-of-concept study of in vivo inflammatory activityMichael Gernert, Marc Schmalzing, Hannah Labinsky, et al.
Pageof 8